A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China
A legfontosabb adatok
- Ki végzi
- Lin Zhong
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 800 fő vett részt
- Kezdés
- 2023. aug. 1.
- Befejezés
- 2025. aug. 1.
- A vizsgálat típusa
- Megfigyeléses, 3 csoport
- A regiszteradat frissítve
- 2026. április 13.
Ki vehet részt
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 9 feltétel megnézéseKevesebb
Ki vehet részt
- Have received their first orthotopic liver transplant (the transplanted liver may be deceased donor or live donor graft) within 10 days prior
- Children group: Age ≤18yeas;
- Adults group: Age >18yeas;
- Willingness to participate in the study
- Ability to understand information material
- Written informed consent
Ki nem vehet részt
- Participation in another investigational agent trial
- Be undergoing multi organ transplant or have undergone prior organ transplant. Have expected life expectancy of less than 72 hours
- Have known Human immunodeficiency virus (HIV) infection (based on testing performed during the transplant evaluation process)
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this observational study is to learn about cytomegalovirus disease epidemiology in pediatric and adult liver transplant recipients in China. The main questions it aims to answer are:
A teljes eredeti leírásKevesebb
* The incidence of Cytomegalovirus (CMV) Infections (including clinical significant CMV reactivations and CMV Diseases) among children and adults Liver transplantation patients in China * All-cause Mortality (Survival probability at 1 year) * Incidence of Allograft Rejection. Number of subjects with allograft rejection * Graft Loss. Incidence of graft loss (re-transplantation) * Late-onset CMV Disease. Incidence of late-onset CMV disease (occurring after 100 days post-randomization) as adjudicated by end point committee * Bacterial Infections. Incidence of bacterial opportunistic infections * Major Fungal Infections. Opportunistic fungal infections * Major Non-CMV Viral Infections. Incidence of non-CMV viral infections We will collect demographic data of participants. All recipients and donors underwent preoperative testing for CMV pp65 antigenemia, plasma CMV DNA, and serum CMV antibody. All the recipients were followed up in a liver transplant follow-up clinic twice weekly for a month after discharge from hospital. After that, patients were followed up weekly for 3 months, fortnightly for 6 months, and monthly for 12 months.
A vizsgálat 3 csoportja
- Prophylaxis Strategy Cohort
Consecutive patients receiving universal antiviral prophylaxis as the standard-of- care CMV prevention strategy post-transplant.
- Preemptive Strategy Cohort
Consecutive patients managed with a preemptive therapy strategy (monitoring and treatment upon viremia) post-transplant.
- No Prevention Strategy Cohort
Consecutive patients who did not receive systematic universal prophylaxis or preemptive therapy for CMV post-transplant.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2026. április 13.